Found 1076 matching trials
ORIENT-31 Regimen in Combination With SBRT for EGFR-mutant Metastatic NSCLC After First-line Third-generation EGFR-TKIs
PHASE2The goal of this prospective study is to explore the safety and preliminary...
Location
Fudan University Shanghai Cancer Center
Study of MK-2206 in Patients With Metastatic Neuroendocrine Tumors (NET)
PHASE2The purpose of this study is to test a new drug called MK-2206. This study ...
Location
Memorial Sloan Kettering Cancer Center
A Study to Evaluate the Safety of Concurrent Durvalumab With CRT Followed by Durvalumab for Chinese Unresectable Stage III NSCLC
PHASE2This is a prospective, multi-center, single arm study assessing the efficac...
Location
Henan Cancer Hospital
Most Closely Human Leukocyte Antigen (HLA)-Matched BK Virus-specific T Lymphocytes (Viralym-B)
PHASE1Patients enrolled on this study will have received a stem cell transplant. ...
Location
Texas Childrens Hospital
An Efficacy and Safety Study for Epoetin Alfa (PROCRIT) in Cancer Patients Not Receiving Chemotherapy or Radiation
PHASE3The purpose of this study is to evaluate the effectiveness and safety of ep...
Location
Multiple Locations
EoE Food Test Pilot Study
NAThe objective of this study is to determine the performance characteristics...
Location
The Children's Hospital of Philadelphia
TACTIC - TAA Specific Cytotoxic T Lymphocytes in Patients With Breast Cancer
PHASE2Status - CLOSED TO PATIENT ENROLLMENT (CNPE)
The study is being conducted ...
Location
Houston Methodist Hospital
Drug Screening Using Novel IMD in Renal Cell Carcinoma
PHASE1This research is being done to study the safety and feasibility of implanti...
Location
Dana-Farber Cancer Institute
Myeloid Derived Suppressor Cells and Chronic Myeloid Leukemia
NAThe suppression of the immune system creates a permissive environment for d...
Location
Multiple Locations
Use of Thalidomide, Lenalidomide, Carfilzomib, Bortezomib and Vorinostat in the Initial Treatment of Newly Diagnosed Multiple Myeloma Patients
PHASE3The purpose of this study is to compare a standard chemotherapy regimen of ...
Location
112 sites UK wide
Treatments Being Tested
Induction (intensive pathway) - cyclophosphamide, lenalidomide, & dexamethasone (CRD) regimenInduction (intensive pathway) - cyclophosphamide, thalidomide, & dexamethasone (CTD) regimenInduction (intensive pathway) - carfilzomib, cyclophosphamide, lenalidomide, & dexamethasone (CCRD) regimenInduction (non-intensive pathway) - cyclophosphamide, lenalidomide, & dexamethasone attenuated (CRDa) regimenInduction (non-intensive pathway) - cyclophosphamide, thalidomide, & dexamethasone attenuated (CTDa) regimenConsolidation (intensive & non-intensive pathways) - bortezomib, cyclophosphamide, & dexamethasone (VCD) regimenMaintenance (intensive & non-intensive pathways) - lenalidomide maintenanceMaintenance (intensive & non-intensive pathways - protocol v5.0 only) - lenalidomide plus vorinostat maintenanceHigh dose melphalan therapy and autologous stem cell transplant (intensive pathway only)